SER insider buying and SEC filings, explained
Serina Therapeutics, Inc. · CIK 1708599
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$75K
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$414K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 7, 2026 | Purchase (code P) | Stephen K. Brannan (Director) bought 1,000 shares at $2.03 ($2K), reported as a purchase (code P). New position of 1,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 9, 2026 |
| May 22, 2026 | Purchase (code P) | Jay Venkatesan (Director) bought 589 shares at $1.78 ($1K), reported as a purchase (code P). New position of 589 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 22, 2026 |
| Jun 11–12, 2026 | Purchase (code P) | Karen J. Wilson (Director) bought 10,100 shares between Jun 11 and Jun 12 at about $1.76 ($18K), reported as a purchase (code P). New position of 10,100 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 21–22, 2026 | Purchase (code P) | Karen J. Wilson (Director) bought 20,000 shares between May 21 and May 22 at about $1.85 ($37K), reported as a purchase (code P). New position of 20,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 19, 2026 | Purchase (code P) | Richard Peter Marshall (Director) bought 12,183 shares at about $1.65 ($20K), reported as a purchase (code P). New position of 12,183 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 22, 2026 |
| Mar 23, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares at about $2.86 ($19K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 24, 2026 |
| Mar 19, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 39,000 shares at $2.50 ($98K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 20, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares at about $3.03 ($20K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Feb 3, 2026 |
| Jan 28, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares at about $3.57 ($23K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 29, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 2,500 shares at $2.95 ($7K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 20–21, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 4,000 shares between Jan 20 and Jan 21 at about $3.04 ($12K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 21, 2026 |
| Jan 13–14, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares between Jan 13 and Jan 14 at about $2.50 ($16K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 14, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 13,000 shares at about $2.69 ($35K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 9, 2026 |
| Dec 23, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 4,100 shares at $2.60 ($11K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 22, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 5,673 shares at about $2.67 ($15K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 3,227 shares at about $2.96 ($10K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 12, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 1,700 shares at about $3.26 ($6K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 16, 2025 |
| Dec 11, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 3,555 shares at about $3.24 ($12K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 12, 2025 |
| Dec 9–10, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 1,245 shares between Dec 9, 2025 and Dec 10, 2025 at about $3.33 ($4K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 11, 2025 |
| Dec 2–3, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares between Dec 2, 2025 and Dec 3, 2025 at about $3.61 ($23K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 25, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 5,965 shares at about $3.90 ($23K), marked as a 10b5-1 plan trade. Holdings down 50% to 5,965 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 535 shares at about $3.94 ($2K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Nov 25, 2025 |
| Nov 18, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares at about $3.75 ($24K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 10, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 6,500 shares at about $4.10 ($27K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 3,398 shares at about $4.24 ($14K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Nov 6, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Randall Moreadith (Chief Scientific Officer) sold 3,102 shares at about $4.40 ($14K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Nov 5, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$75K in purchases since May 19, 2026 · Purchases traded May 19, 2026 to Jun 12, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Richard Peter Marshall (Director) | $20K | May 19, 2026 | SEC filing |
| Karen J. Wilson (Director) | $37K | May 22, 2026 | SEC filing |
| Karen J. Wilson (Director) | $18K | Jun 12, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SER in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.